Articles citing this paper
Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme
Jonathan Karnon A C , Laura Edney A and Michael Sorich B
+ Author Affiliations
- Author Affiliations
A School of Public Health, University of Adelaide, Level 7, 178 North Terrace, Adelaide, SA 5005, Australia. Email: laura.edney@adelaide.edu.au
B School of Medicine, Flinders University, GPO Box 2100, Adelaide, SA 5001, Australia. Email: michael.sorich@flinders.edu.au
C Corresponding author. Email: jonathan.karnon@adelaide.edu.au
Australian Health Review 41(1) 1-6 https://doi.org/10.1071/AH15122
Submitted: 26 June 2015 Accepted: 1 February 2016 Published: 9 March 2016
9 articles found in Crossref database.
The political economy of the assessment of value of new health technologies
Karnon Jonathan,
Edney Laura, Afzali Hossein
Journal of Health Services Research & Policy. 2018 23(2). p.116
Time to rethink our approach to the Pharmaceutical Benefits Scheme (PBS) listing of medicines: the case of pregabalin
Winckel Karl,
Daglish Mark,
Pache David, Hollingworth Samantha A.
Australian Health Review. 2020 45(2). p.261
Cost‐effectiveness in surgery: concepts of cost‐utility analysis explained
Vissapragada Ravi,
Bulamu Norma,
Karnon Jonathan,
Yazbek Roger, Watson David I.
ANZ Journal of Surgery. 2021 91(9). p.1717
Effect of a state hospital formulary on medicines utilisation in Australia
Iedema Joel
Australian Health Review. 2021 45(6). p.704
Who benefits from fixed‐dose combinations? Two‐year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy
Schaffer Andrea L.,
Buckley Nicholas A., Pearson Sallie‐Anne
Pharmacoepidemiology and Drug Safety. 2017 26(12). p.1465
Challenges for Medicare and universal health care in Australia since 2000
Angeles Mary Rose,
Crosland Paul, Hensher Martin
Medical Journal of Australia. 2023 218(7). p.322
Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure
Lee Leonard, Kim Hansoo
Value in Health Regional Issues. 2024 40 p.27
Therapeutic Substitution in Response to Patent Expiry? Statins in Australia*
Bates Christopher, Méndez Susan J.
Economic Papers: A journal of applied economics and policy. 2023
What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia
Karnon Jonathan,
Shafie Ainul Shakirah,
Orji Nneka, Usman Sofoora Kawsar
Cost Effectiveness and Resource Allocation. 2016 14(1).
